the T allele of HTR2C rs3813929 was found to be associated with protection against weight gain in Asians [18] and Caucasians [19] , the A allele of LEP rs7799309 was associated with weight gain in Asians [20, 21] and the G allele was associated with weight gain in Caucasians [19, 22] , suggesting that racial variations may underlie the difference. Hence, in this study, we aimed to identify which of the candidate SNPs are associated with the occurrence of MS within our multiethnic Asian population.
Materials & methods n Patient recruitment
A total of 206 schizophrenia patients aged between 18 and 65 years were recruited, each of whom fulfilled the criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision [23] , for the diagnosis of schizophrenia. The determination of MS was made on the basis of NCEP ATPIII criteria modified for Asian subjects [24] . MS is said to be present in an individual when at least three of the following criteria are met: abdominal obesity (waist circumference ≥90 cm in men and ≥80 cm in women); raised triglyceride levels (≥1.7 mmol/l); reduced HDL cholesterol level (<1.03 mmol/l in men or <1.29 mmol/l in women); raised blood pressure (systolic ≥130 mmHg and/or diastolic ≥85 mmHg) or current use of antihypertensives; and raised fasting blood glucose level (≥5.6 mmol/l). Patients who were already on antihypertensive or antidiabetic medications at the time of recruitment are considered to have high blood pressure or high fasting blood glucose, respectively. The study participants were outpatients at the University of Malaya Medical Centre (UMMC) and five other hospitals throughout Malaysia under the Ministry of Health (MOH): Terendak Army Hospital (Melaka), Lumut Navy Hospital (Perak), Hospital Bahagia Ulu Kinta (Perak), Hospital Permai (Johor) and Hospital Sentosa Kuching (Sarawak). Patients needed to be taking either typical or atypical AP treatment for at least 1 year and not taking any mood stabilizers. The mean duration of AP treatment was 4.52 ± 5.37 years. Any patients who had already started receiving antihypertensive, antidiabetic or antihyperlipidemia treatment for ≥3 months prior to screening were also included. Exclusion criteria included patients with a history of diabetes mellitus or hypertension prior to the treatment of schizophrenia. The study protocol was approved by the UMMC and the MOH ethics committees. Patients were given study information sheets and patients gave written informed consent prior to blood collection. n Genetic analyses DNA was obtained from peripheral blood and was extracted according to the manufacturer's protocol (QIAamp ® DNA Blood Mini Kit, Qiagen, Hilden, Germany). Genotyping of all polymorphisms was carried out at the Genome Research Centre (University of Hong Kong) with the Sequenom MassARR Ay technology platform (Sequenom, CA, USA). DNA purity was greater than 1.8 absorbance ratio (A260/A280) to ensure high-quality and was diluted to a concentration of 10-20 ng/µl. Five duplicates were genotyped for every 90 samples (89 DNA and one control) and one blank. For data acquisition and ana lysis, the MassARRAy ® Typer 4.0 software was used. Using the default setting of Gaussian mixture model, genotypes were called after cluster ana lysis. Inspection of the clusters was carried out to ensure a clear cluster separation with satisfactory signal to noise cutoff. SpectroChip with less than 99.5% concordance in duplicate checks along with more than 10% call rate in blank check, or with more than 25% call rate in the blank control, were considered failed and would be repeated. n Clinical & laboratory assessments Cross-sectional measurements of weight, height, waist and hip circumference, and blood pressure were taken. Lipid levels (HDL, low-density lipoprotein, total cholesterol, fasting glucose and triglycerides) were measured from the blood collected, and then sent to the Clinical Diagnostic Laboratory of UMMC for analyses of the various para meters. BMI was obtained by measuring each patient's height and weight (BMI = kg/m 2 ). Obesity was defined as having a BMI of 30 kg/m 2 or more. n Statistical analyses The estimated sample size to provide a desired power of at least 80% is 74, under the following assumptions: allele frequency ranges from 0.2-0.5, mean and standard deviation of BMI in the population is 27.89 ± 5.06 kg/m 2 , R 2 ranges from 0. ) . However, bodyweight, BMI, other metabolic parameters (waist circumference, systolic blood pressure, diastolic blood pressure, and glucose and triglyceride levels) and leptin levels were significantly higher in those with MS. HDL levels were significantly lower in those with MS. The patients received olanzapine (n = 62), risperidone (n = 59) and paliperidone (n = 24)and other APs, which included both typical and atypical APs (n = 61). Fifty-nine patients out of the total subjects were obese (29.0%). Of these patients, 42 had MS and 48 were taking atypical APs. Table 2 summarizes all 16 polymorphisms with the minor allele frequencies and p-values of the allelic association of each polymorphism with MS. Of these, only three SNPs showed an association after adjustment for age, ethnic group, gender and BMI: the FTO rs9939609 (T vs A), LEPR rs1137101 (A vs G) and MTHFR rs1801133 (C vs T) gene polymorphisms. Table 3 lists results of post hoc analyses of the significant allelic associations, tested by using alternative genetic modeling. The occurrence of MS was found to be associated with the A allele carriers of FTO rs9939609 (TT vs TA+AA, p = 0.047); the GG/G allele carriers of LEPR rs1137101 (AA+AG vs GG, p = 0.022; AA vs AG+GG, p = 0.026); and the T allele carriers of MTHFR rs1801133 (CC vs CT+TT, p = 0.016). None of the individual variables contributing to the diagnosis of MS showed a significant association with allele frequency of any of these three polymorphisms.
discussion
In the present study, from the total polymorphisms studied, only FTO rs9939609, LEPR rs1137101 and MTHFR rs1801133 showed significant associations with MS in chronic schizophrenia patients who were receiving AP treatment. Notably the effect for each gene was with the diagnosis of MS and not with any of its component factors. In terms of frequency, the A allele of FTO rs9939609 and the T allele of MTHFR rs1801133 occur less frequently in our study population than in Caucasians (FTO: Utah residents with Northern and Western European ancestry from the CEPH collection [CEU] = 0.46; MTHFR: CEU = 0.31) whereas the G allele of LEPR rs1137101 occurs more frequently in our population than in Caucasians, as reported in HapMap (CEU = 0.47).
We found that FTO rs9939609 is associated with the occurrence of MS in patients receiving APs. In chronic schizophrenia patients of Irish/British descent, the A allele was found to be associated with body fat mass, manifested by its association with waist circumference, waistto-hip ratio and central obesity [13] . In terms of AP-induced weight gain, one study failed to report any association with carriers of the A allele (n = 160) [3] , while another reported a significant association of the A allele with a higher BMI prior to treatment, but not with weight gain after a year of taking APs (n = 165) [25] .
The positive association reported by our study and in the Irish/British patients suggests longterm effect of FTO genotypes in predisposing patients to either MS or obesity, as both studies involved patients with a high and intermediate future science group propensity towards weight gain who were receiving long-term AP treatment with clozapine, olanzapine and risperidone [12, 13] . The association of the A allele with BMI was reported to be fourfold higher (1.6 kg/m 2 increase in BMI per A allele) in patients receiving long-term AP treatment [13] , which is higher than that seen in the general population with obesity (0.36 kg/m 2 increase in BMI per A allele) [26] . However, following an observation period of a year, this polymorphism showed no association with weight gain in first-episode Spanish schizophrenia patients [25] and within German patients after a 3-month follow-up [3] . This finding indicates that both AP and duration of AP treatment may contribute to the significant association of the FTO SNP.
In the general population, the A allele of rs9939609 has been known to be associated with adiposity in Caucasians and Asians [27] [28] [29] [30] and with obesity in various populations [26, [31] [32] [33] [34] . The exact mechanism for how this gene affects BMI and obesity remains unclear, but it was hypothesized that the FTO gene is involved in food intake, as it is highly expressed in the hypothalamus [35] and was also found to be involved in leptin signaling at the hypothalamus [36] . Animal studies showed that this gene controls energy expenditure and its absence in mice resulted in a leaner body mass and reduced adipocytes [37, 38] . Unlike the SNP on the FTO gene, the association of LEPR rs1137101 with MS in our study indicated a protective effect of the G allele against MS. This is not in line with previous reports in which the G allele was associated with an increased risk of obesity in female schizophrenia patients (n = 200) [4] and with an increased ratio of total cholesterol:HDL that mirrors the risk for CVD (n = 353) [39] . Both studies were performed in The Netherlands in patients who had been receiving atypical AP treatment for at least 3 months, most of whom were taking clozapine and olanzapine. Similarly, the presence of the G allele from both LEPR and LEP gene polymorphisms was associated with increased BMI changes in Americans (n = 37) after 6 weeks of olanzapine treatment [22] , suggesting variations in ethnicities as a possible contributor to the difference.
The deviation of rs1137101 from HWE in this study is probably owing to the small number of samples or because the population studied comprised schizophrenia patients only, without the inclusion of healthy subjects. Regarding the genotype frequency of rs1137101, the paucity in heterozygotes and excess in homozygotes has resulted in deviation from HWE. Allele frequencies are consistent with other Asian samples Factors potentially contributing to deviation from HWE in this sample include nonrandom mating, migration of the population and mutation [40] . We are excluding genotyping error as a source of deviation owing to the rigorous quality control that is applied in Sequenom genotyping; it is a widely used methodology as a result of its high rates of success for multiplex assay design and its high data quality [41] [42] [43] .
Similar to what was observed with LEPR rs1137101, the T allele of MTHFR rs1801133 (677C/T) appears to be protective against MS in our schizophrenia patients. The first report by Ellingrod and colleagues in Caucasian adults showed that the T allele imposed a 3.6-fold increased risk of MS in patients who had been taking an AP for at least a year [44] . Another group also found an association of T allele carriers with MS in young patients (≤18 years old) receiving atypical APs (72% were of European descent) [45] . Other studies, however, failed to find any association of the T allele with MS in 518 patients comprising mostly white Caucasians (~90%) [46] and in a genome-wide association study in patients of mixed ethnicities It would appear that a large sample size and a long follow-up period do not guarantee a significant finding for this polymorphism. Nevertheless, the difference in ethnicity might, again, contribute to the difference in the role played by the T allele towards MS, as seen in this study. MTHFR controls the production of S-adenosyl methionine, which is the source of the methyl group that allows DNA methylation to occur [45, 48] . An initial report in a study among healthy Mexican-American women found that low DNA methylation occurred in carriers of the TT genotype [49] . The same observation was seen in female schizophrenia patients with the TT genotype that lead to a higher number of MS among women [50] , although gender was not a contributing factor in this study.
Considering that the frequency of the T allele is low in our study, even when compared with other Asian populations, as listed in the HapMap project (CHB = 0.49; JPT = 0.39), this fact might underlie the protective effect of the allele. The TT genotype decreases approximately 65-70% of the enzymatic activity of MTHFR, leading to hyperhomocysteinemia [51] , which is associated with an increased risk of CVD [52, 53] , further leading to MS. Thus, having a low T allele frequency might partially underlie the protective effect seen in our population.
In the general and nonpsychiatric population, the MTHFR gene has been associated with obesity [54, 55] and insulin resistance [56] , but no association was seen in a genome-wide association study with obesity/diabetes and BMI [57, 58] . The 677C/T polymorphism, specifically, has also been reported to be associated with coronary artery disease [59, 60] , diabetes [61] , diabetic nephropathy [62] , carotid stenosis and hypertension [63, 64] .
Apart from genetic variations, negative symptoms of schizophrenia and other environmental factors such as diet and physical activity can contribute to the occurrence of MS among patients.
Some limitations of this study include its small sample size, although it must be borne in mind that previous studies with a similar sample size have been previously published [13, 19, 65] , and the fact that our patients were among those receiving long-term AP treatment. Thus we cannot conclude that the MS was due to AP intake alone, as the study included patients who were also taking other medications such as anti diabetics and antihypertensives, some of which may also cause weight gain [66, 67] . As previously mentioned, the study has 80% power with a minimum of 74 samples. With the sample size we have (206 patients); the study has 95% power.
The number of SNPs per gene chosen in this study is limited to only one or two and, although focusing on what are primarily functional SNPs with strong evidence for their potential involvement in metabolic dysfunction, this does not reflect the full genetic variability of the genes studied.
We did not have a record of prior AP use other than the current AP that the patients were taking (listed in Table 1) , as this was a cross-sectional study at one time point. We aimed to observe the association of the selected polymorphisms with MS occurrence; thus, knowing which AP most patients were taking was not a main concern, as some of the typical APs and most atypical APs are already known to cause weight gain and other metabolic problems [68] .
In order to avoid type II errors we did not apply a correction for multiple testing; however, each gene and polymorphism chosen for investigation had evidence implicating its role in AP druginduced effects on bodyweight, thus a separate hypothesis for each gene provided a justification for this approach. Nevertheless, replication in further patient cohorts is necessary before we can generalize these genetic associations with the metabolic consequences of AP drug treatment.
Conclusion
We found evidence of an association between FTO rs9939609, LEPR rs1137101 and MTHFR 
